AbbVie Seeks U.S., European OK of Rinvoq in Eczema
October 19 2020 - 10:53AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Monday said it has filed with the U.S. Food and
Drug Administration and the European Medicines Agency for expanded
approval of Rinvoq for the treatment of adults and adolescents with
moderate to severe atopic dermatitis, a chronic, inflammatory skin
disease more widely known as eczema.
The North Chicago, Ill., biopharmaceutical company said the
applications are supported by data from three pivotal phase 3
studies in which Rinvoq showed significant improvement in skin
clearance and reduction in itch compared with placebo.
AbbVie last year received U.S. and European approval for Rinvoq
for adults with moderately to severely active rheumatoid arthritis.
The company in August filed for U.S. and European approval for the
drug in adults with active ankylosing spondylitis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 19, 2020 10:38 ET (14:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024